Related Experiment Video

Updated: Jun 20, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Plasma levels of lipoprotein (a) in patients with major depressive disorders

Sharareh Hamidifard1, Ali Fakhari, Soltanali Mahboob

  • 1Department of Biochemistry, Nutrition and Diet Therapy, Nutritional Research Center, Tabriz University of Medical Sciences, Iran.

Psychiatry Research
|September 15, 2009
PubMed

Insights

Major depressive disorder patients exhibit higher lipoprotein (a) (Lp(a)) levels, a key factor in atherosclerosis. This finding suggests a potential link between depression and increased cardiovascular disease risk.

Area of Science:

  • Cardiology
  • Psychiatry
  • Biochemistry

Background:

  • Depression is a significant risk factor for cardiovascular disease (CVD) development and progression.
  • The precise mechanisms linking depression to CVD remain unclear.
  • Elevated lipoprotein (a) (Lp(a)) is implicated in atherosclerosis and coronary heart disease progression.

Purpose of the Study:

  • To investigate plasma lipoprotein (a) (Lp(a)) levels in patients with major depressive disorder (MDD).
  • To compare Lp(a) levels between MDD patients and healthy controls.
  • To explore the potential contribution of Lp(a) to cardiovascular risk in depression.

Main Methods:

  • Plasma Lp(a) levels were measured in 35 MDD patients and 35 age- and gender-matched healthy controls.
  • An immunoturbidimetric method was used for Lp(a) quantification.
  • Total cholesterol levels were also assessed.

Main Results:

  • Total cholesterol was significantly lower in the MDD group compared to controls.
  • Patients with MDD showed significantly higher plasma Lp(a) levels than healthy controls (34.94+/-18.01 vs. 20.08+/-11.27 mg/dl).

Conclusions:

  • Increased Lp(a) levels may contribute to elevated cardiovascular risk in individuals with major depressive disorder.
  • This study highlights a potential biomarker for cardiovascular risk in depression.
  • Further research is warranted to elucidate the relationship between depression, Lp(a), and cardiovascular outcomes.

More Related Videos

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...